<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rizzo, Toni</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Smolen, Josef S.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">EULAR Updates Recommendations for the Management of RA</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-01-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">26-27</style></pages><abstract><style  face="normal" font="default" size="100%">The first European League Against Rheumatism (EULAR) recommendations for the management of rheumatoid arthritis (RA) with synthetic and biologic disease-modifying antirheumatic drugs (DMARDs) were published in 2010 [Smolen JS et al. Ann Rheum Dis 2010]. A task force proposed updated recommendations in April 2013. This article discusses the the 2013 preliminary recommendations. which are based on three systemic literature reviews on the following topics: 1) DMARDs; 2) biologic DMARDs; and 3) safety issues.</style></abstract><number><style face="normal" font="default" size="100%">18</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>